v3.26.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash and cash equivalents $ 3,198,682 $ 10,651,644 $ 10,445,404
Revenue concentration risk, amount (1,653,007) 227,956  
Reduction of equipment revenue 1,900,000    
Unearned revenue 90,666 170,000  
Revenue equipment receive 1,900,000    
Depreciation expense 678,656 156,002  
Research and Development Cost 2,524,519 2,143,471  
Revenue receive as consideration 812,000    
Costs and expenses 68,000    
Allocated transaction price 498,000    
Capitalized costs 91,100    
Contract costs 45,550    
Incurred costs in excess 1,900,000    
Revenue recognition, milestone method 270,667    
Inventory allowance 50,000 50,000  
Revenues 215,037 445,445  
Unbilled receivables 0 1,653,007  
Contract loss provision 1,600,000 1,000,000  
Treatability study services [Member]      
Revenues 645,000 217,000  
Full-scale demonstration [Member]      
Revenues 953,000 $ 25,000  
Unbilled receivables $ 1,900,000    
Unvested Restricted Stock [Member]      
Antidilutive Excluded from Computation of Earnings Per Share, Amount 865,296 354,929  
Warrants [Member]      
Antidilutive Excluded from Computation of Earnings Per Share, Amount 877,524 1,467,524  
Options [Member]      
Antidilutive Excluded from Computation of Earnings Per Share, Amount 1,708,637 1,584,312